ANABV
AnaptysBio, Inc. Common Stock When IssuedNASDAQ
Key Statistics
Market Cap
—
P/E Ratio
—
EPS
—
Beta
0.41
52W High
$49.76
52W Low
$41.99
50-Day MA
$44.84
200-Day MA
$44.84
Dividend Yield
—
Profit Margin
-5.64%
Forward P/E
—
PEG Ratio
—
About AnaptysBio, Inc. Common Stock When Issued
AnaptysBio, Inc. is a clinical-stage biotechnology company dedicated to the discovery and development of innovative antibody therapeutics targeting severe diseases, with a particular focus on immunology and oncology. Utilizing its proprietary platform, AnaptysBio excels in generating high-quality, diverse monoclonal antibodies that address significant unmet medical needs. The company boasts a promising pipeline of therapeutic candidates in clinical trials, demonstrating its commitment to advancing antibody-based therapies. Through strategic partnerships and a robust development framework, AnaptysBio aims to deliver transformative treatments that enhance patient outcomes in critical therapeutic areas.
Fundamentals
| Revenue (TTM) | $234.60M |
| Gross Profit (TTM) | $98.63M |
| EBITDA | $48.45M |
| Operating Margin | 61.80% |
| Return on Equity | -24.50% |
| Return on Assets | 7.06% |
| Revenue/Share (TTM) | $8.16 |
| Book Value | $1.33 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 151.10% |
| Shares Outstanding | 0 |
| Float | $17.26M |
| % Insiders | 0.00% |
| % Institutions | 0.00% |
Data last updated: 5/25/2026